Evolus (NASDAQ:EOLS) Posts Earnings Results, Misses Estimates By $0.21 EPS

Key Points

• Evolus reported earnings of ($0.30) per share for the quarter, falling short of analysts' expectations by ($0.21) EPS.
• The company has a negative net margin of 20.40% and a staggering negative return on equity of 759.04%.
• Despite the earnings miss, multiple analysts have reiterated "buy" ratings with target prices ranging from $21.00 to $27.00.

Evolus (NASDAQ:EOLS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.21), Zacks reports. Evolus had a negative return on equity of 3,474.21% and a negative net margin of 22.31%. The business had revenue of $69.39 million for the quarter, compared to analysts' expectations of $82.18 million. During the same period in the previous year, the firm posted ($0.18) EPS. The firm's revenue for the quarter was up 3.7% compared to the same quarter last year. Evolus updated its FY 2025 guidance to EPS.

Evolus Price Performance

EOLS traded down $0.17 during midday trading on Friday, hitting $5.90. The stock had a trading volume of 2,722,368 shares, compared to its average volume of 1,984,819. The company has a market cap of $381.61 million, a P/E ratio of -6.02 and a beta of 1.12. The business has a fifty day moving average of $9.25 and a 200 day moving average of $11.14. The company has a debt-to-equity ratio of 22.00, a quick ratio of 2.16 and a current ratio of 2.27. Evolus has a 1 year low of $5.85 and a 1 year high of $17.82.

Insider Transactions at Evolus

In other Evolus news, insider Rui Avelar sold 3,385 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the sale, the insider owned 359,082 shares of the company's stock, valued at $3,544,139.34. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sandra Beaver sold 6,494 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total value of $65,069.88. Following the completion of the sale, the chief financial officer directly owned 167,089 shares of the company's stock, valued at approximately $1,674,231.78. This represents a 3.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold 153,571 shares of company stock worth $1,537,090 in the last three months. Corporate insiders own 5.90% of the company's stock.

Institutional Trading of Evolus

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Evolus by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company's stock valued at $400,000 after purchasing an additional 1,838 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in Evolus in the first quarter valued at approximately $158,000. Millennium Management LLC lifted its position in Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after purchasing an additional 23,605 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company's stock valued at $1,883,000 after purchasing an additional 41,513 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company's stock valued at $841,000 after purchasing an additional 57,987 shares during the last quarter. Institutional investors own 90.69% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright cut their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday. BTIG Research cut their price objective on Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Needham & Company LLC reissued a "hold" rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $21.25.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.